Claudine Sapède is Director, Global HTA Policy at Novartis. In this role, she focuses on value assessment, HTA and reimbursement decision-making approaches and their impact on patient access to innovative treatments. She engages with internal and external stakeholders involved in shaping HTA, pricing and reimbursement decisions. Claudine is currently a member of the EFPIA market access and HTA working groups, leading the workstream related to the implementation of the EU HTA Reg. Prior to this, she had different roles in the field of pricing and market access, at country and global levels. Her career of over 20 y in the pharma sector spans the full spectrum of evidence generation, value demonstration, MA strategies, pricing, and policy.

Generalist with a broad understanding of policies across value chain in pharmaceutical and health sector. Stakeholder, alliance and project management expertise.

Lara Wolfson, PhD, is the Associate VP and Head of HTA Statistics at MSD in Zurich, Switzerland. Leading a team of 75+ statisticians, she pioneers quantitative solutions for Health Technology Assessment (HTA) challenges. Lara's career spans roles at Merck, Janssen, and the World Health Organization, focusing on vaccines, epidemiology, and health economics. She also taught at Brigham Young University and the University of Waterloo. Dr. Wolfson co-leads the HTA ESIG of EFSPI and holds MS and PhD degrees in Statistics from Carnegie Mellon University, with an undergraduate background from Simon Fraser University.

Matias Olsen is the Public Affairs and Policy Manager for the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). Matias supports EUCOPE on key topics, including the implementation of EU HTA, advanced diagnostics, RWE, the Patent Package, Europe’s Beating Cancer Plan and relevant market access topics. He coordinates members’ thematic working groups, including the P&R/Market Access Working Group, the Genomics Working Group and the EU HTA Regulation Task Force. Matias has previously advocated on behalf of European cancer patients and worked in the Norwegian Social Security Administration, with reimbursement of medical devices and coordination of social security within the EU/EEA.